In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Thomas O'Hare, Denise K. Walters, Eric P. Stoffregen, Taiping Jia, Paul W. Manley, Jürgen Mestan, Sandra W. Cowan-Jacob, Francis Y. Lee, Michael Heinrich, Michael W N Deininger, Brian Druker

Research output: Contribution to journalArticle

810 Citations (Scopus)

Abstract

Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.

Original languageEnglish (US)
Pages (from-to)4500-4505
Number of pages6
JournalCancer Research
Volume65
Issue number11
DOIs
StatePublished - Jun 1 2005

Fingerprint

Phosphotransferases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl Fusion Proteins
In Vitro Techniques
Dasatinib
Imatinib Mesylate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Recurrence
Clinical Trials
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. / O'Hare, Thomas; Walters, Denise K.; Stoffregen, Eric P.; Jia, Taiping; Manley, Paul W.; Mestan, Jürgen; Cowan-Jacob, Sandra W.; Lee, Francis Y.; Heinrich, Michael; Deininger, Michael W N; Druker, Brian.

In: Cancer Research, Vol. 65, No. 11, 01.06.2005, p. 4500-4505.

Research output: Contribution to journalArticle

O'Hare, T, Walters, DK, Stoffregen, EP, Jia, T, Manley, PW, Mestan, J, Cowan-Jacob, SW, Lee, FY, Heinrich, M, Deininger, MWN & Druker, B 2005, 'In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants', Cancer Research, vol. 65, no. 11, pp. 4500-4505. https://doi.org/10.1158/0008-5472.CAN-05-0259
O'Hare, Thomas ; Walters, Denise K. ; Stoffregen, Eric P. ; Jia, Taiping ; Manley, Paul W. ; Mestan, Jürgen ; Cowan-Jacob, Sandra W. ; Lee, Francis Y. ; Heinrich, Michael ; Deininger, Michael W N ; Druker, Brian. / In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. In: Cancer Research. 2005 ; Vol. 65, No. 11. pp. 4500-4505.
@article{bc2177c2a041484dab03666d6e1179f8,
title = "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants",
abstract = "Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90{\%} of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.",
author = "Thomas O'Hare and Walters, {Denise K.} and Stoffregen, {Eric P.} and Taiping Jia and Manley, {Paul W.} and J{\"u}rgen Mestan and Cowan-Jacob, {Sandra W.} and Lee, {Francis Y.} and Michael Heinrich and Deininger, {Michael W N} and Brian Druker",
year = "2005",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-05-0259",
language = "English (US)",
volume = "65",
pages = "4500--4505",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

AU - O'Hare, Thomas

AU - Walters, Denise K.

AU - Stoffregen, Eric P.

AU - Jia, Taiping

AU - Manley, Paul W.

AU - Mestan, Jürgen

AU - Cowan-Jacob, Sandra W.

AU - Lee, Francis Y.

AU - Heinrich, Michael

AU - Deininger, Michael W N

AU - Druker, Brian

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.

AB - Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.

UR - http://www.scopus.com/inward/record.url?scp=21144451094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144451094&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0259

DO - 10.1158/0008-5472.CAN-05-0259

M3 - Article

VL - 65

SP - 4500

EP - 4505

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -